CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
Authors
Keywords
-
Journal
Clinical and Translational Medicine
Volume 12, Issue 8, Pages -
Publisher
Wiley
Online
2022-08-01
DOI
10.1002/ctm2.943
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells
- (2021) Gabriela Andrejeva et al. JOURNAL OF IMMUNOLOGY
- Functions of Thrombospondin-1 in the Tumor Microenvironment
- (2021) Sukhbir Kaur et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CD70 antibody‐drug conjugate: A potential novel therapeutic agent for ovarian cancer
- (2021) Mayu Shiomi et al. CANCER SCIENCE
- First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.
- (2021) Aflah Roohullah et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.
- (2021) Stéphane Champiat et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study.
- (2021) Hui Kong Gan et al. JOURNAL OF CLINICAL ONCOLOGY
- Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
- (2021) Rosalynd Upton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4+ BTLA+ T Cells in Tumor Microenvironment of Mycosis Fungoides
- (2021) Tony T. Jiang et al. Cancers
- A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.
- (2020) George A. Fisher et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
- (2020) Jennifer Sun et al. Cancers
- Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody.
- (2020) Amita Patnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
- (2020) Gabriela Pavlasova et al. HAEMATOLOGICA
- Targeting cluster of differentiation�47 improves the efficacy of anti‑cytotoxic T‑lymphocyte associated protein�4 treatment via antigen presentation enhancement in pancreatic ductal adenocarcinoma
- (2020) Xifu Song et al. Experimental and Therapeutic Medicine
- Aging‐associated changes in CD47 arrangement and interaction with thrombospondin‐1 on red blood cells visualized by super‐resolution imaging
- (2020) Feng Wang et al. AGING CELL
- Dissecting Clonal Heterogeneity in AML
- (2020) Jan Jacob Schuringa et al. CANCER CELL
- Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma
- (2018) Xuyao Zhang et al. CARCINOGENESIS
- Ublituximab for the treatment of CD20 positive B-cell malignancies
- (2018) Hani M. Babiker et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Chemotherapy induces enrichment of CD47+/CD73+/PDL1+immune evasive triple-negative breast cancer cells
- (2018) Debangshu Samanta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion
- (2018) Xiaojuan Liu et al. Cell Reports
- CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping
- (2018) Anne E. Bras et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
- (2018) Ranjana Advani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses
- (2017) Boning Liu et al. mAbs
- Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies
- (2017) Elie Dheilly et al. MOLECULAR THERAPY
- SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin
- (2017) Jun Chen et al. NATURE
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model
- (2017) Hua Tao et al. ONCOLOGY RESEARCH
- Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity
- (2017) Nan Guo Ring et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies
- (2017) E C Pietsch et al. Blood Cancer Journal
- SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells
- (2017) Laia Pascual Ponce et al. Oncotarget
- CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
- (2017) Peter E. van Bommel et al. OncoImmunology
- Durable antitumor responses to CD47 blockade require adaptive immune stimulation
- (2016) Jonathan T. Sockolosky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the ‘real life’ setting: A single center observational study
- (2015) Sotirios G. Papageorgiou et al. Hematology
- A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells
- (2015) Emily C Piccione et al. mAbs
- Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency
- (2015) Yun Yang et al. mAbs
- CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
- (2015) Xiaojuan Liu et al. NATURE MEDICINE
- Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
- (2015) Jie Liu et al. PLoS One
- Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
- (2013) D. Tseng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
- (2012) S. B. Willingham et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Heparan Sulfate Modification of the Transmembrane Receptor CD47 Is Necessary for Inhibition of T Cell Receptor Signaling by Thrombospondin-1
- (2011) Sukhbir Kaur et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47
- (2010) M. P. Chao et al. Science Translational Medicine
- Rituximab: Mechanism of Action
- (2010) George J. Weiner SEMINARS IN HEMATOLOGY
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Radioprotection in Normal Tissue and Delayed Tumor Growth by Blockade of CD47 Signaling
- (2009) J. B. Maxhimer et al. Science Translational Medicine
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now